NEW YORK (GenomeWeb) – The New York Genome Center has named Harold Swerdlow its VP of Technology Innovation.

In the role, he will be responsible for developing technologies to be used in genomics research and in clinical applications, including microfluidic tools for reducing the cost of single-cell and other DNA preparation methods for next-generation sequencing.

Swerdlow formerly was head of R&D at the Wellcome Trust Sanger Institute, he formerly was chief technology officer at Dolomite, and he was senior director of research at Solexa.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.